Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.

EQS-News: Redcare Pharmacy N.V. / Key word(s): Development of Sales/Preliminary Results Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.  06.10.2025 / 06:45 CET/CEST The issuer is solely responsible for the content of this announcement. Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.

• Total sales up 25% to EUR 719M in Q3.
• YTD total sales up 27% or EUR 450M to EUR 2.15bn.
• Non-Rx sales up 17% to EUR 448M in Q3; YTD 18% to EUR 1.4bn.
• Rx sales in Germany up 82% to EUR 126M in Q3, YTD 122% and EUR 348M.
• Number of active customers up 0.2M, reaching 13.7M. NPS up, to well over 70.
• Company reaffirms all elements of full-year guidance.

Sevenum, the Netherlands, 6 October 2025. Redcare Pharmacy N.V. today announced its preliminary and unaudited third quarter sales numbers. The Group’s total sales increased 25.2% to EUR 719 million (Q3 2024: EUR 575 million). Both reporting segments, DACH and International, achieved over 25% fully organic sales growth in Q3, 25.2% and 25.4% respectively. Non-Rx sales increased 16.7% to EUR 448 million (Q3 2024: EUR 383 million) and total Rx sales 42.3% to EUR 272 million (Q3 2024: EUR 191 million). In Germany, Rx sales totaled EUR 126 million, an increase of 82.1% year over year (Q3 2024: EUR 69 million). At the end of the quarter, Redcare Pharmacy recorded 13.7 million active customers and a significant improvement in the net promoter score (NPS) to well over 70, vs. 64 in H1 of the current year.

Redcare Pharmacy’s CEO Olaf Heinrich comments: “We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance. Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%.”

Strong momentum in Rx.

Entering Q4 with accelerated Rx growth in Germany and the customary seasonal uplift in order volumes in the final quarter of the year, the Group remains on track to achieve at least EUR 500 million Rx sales for the year. Accordingly, Redcare Pharmacy reaffirms its full-year guidance for Rx, as well as for all other elements.